Catarina Serra-Almeida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Catarina Serra-Almeida has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Liliana Bernardino
Department of Medical Sciences, Faculty of Health Sciences, RISE-Health, UBI, University of Beira Interior, Covilhã, Portugal
4 shared publications - Cláudia Saraiva
Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg
3 shared publications Alise Zagare
Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg
1 shared publication- Ana Clara Cristovao
Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Avenida Infante D. Henrique, 6200-506 Covilhã, Portugal
1 shared publication - Ana Margarida Vale
Department of Medical Sciences, Faculty of Health Sciences, RISE-Health, UBI, University of Beira Interior, Covilhã, Portugal
1 shared publication - Elisabete Ferreiro
CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
1 shared publication
Latest Publications
- Open Access
- 4 November 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
Histamine-Induced Peripheral Priming Promotes Region-Specific Glial Remodelling and Protects Against Dopaminergic Injury in a Mouse Model of Parkinson’s Disease
Peripheral immune priming can induce long-lasting changes in brain innate immune responses. In neurological diseases, including Alzheimer’s disease and stroke, inflammatory priming has been associated with neuroprotection, likely through microglial reprogramming. Here, we evaluated whether repeated peripheral histamine exposure was associated with persistent glial morphometric remodelling and with an altered response to subsequent dopaminergic injury. Adult male mice received four consecutive daily intraperitoneal injections of histamine, lipopolysaccharide (LPS), used as a reference peripheral immune-stimulating condition, or PBS. Three weeks later, glial morphometry was assessed in the substantia nigra (SN) and striatum (ST). In a separate cohort, mice underwent intrastriatal 6-hydroxydopamine (6-OHDA) lesion three weeks after priming. Motor behaviour, nigrostriatal TH immunoreactivity, apomorphine-evoked striatal neuronal recruitment and glial morphometric response were evaluated two weeks later. Under non-lesioned conditions, histamine and LPS exposure were associated with persistent microglial morphometric remodelling in the SN, whereas comparable ST changes were detected only after LPS. Astrocytic GFAP-based measures showed modest, non-significant trends in the SN. Following 6-OHDA lesion, prior histamine or LPS exposure reduced apomorphine-induced rotational asymmetry and was associated with greater preservation of tyrosine hydroxylase (TH) immunoreactivity in the nigrostriatal system. Histamine priming additionally increased apomorphine-evoked recruitment of DARPP-32-positive striatal neurons and attenuated lesion-associated microglial changes in the SN and ST. Astrocytic responses after lesion were region-dependent. Repeated peripheral histamine exposure was associated with persistent, region-specific glial morphometric remodelling and attenuated behavioural and dopaminergic deficits following subsequent 6-OHDA injury. These findings are compatible with long-lasting histamine-associated neuroimmune conditioning, although the underlying cellular and molecular mechanisms and the causal contribution of glial remodelling remain to be established. Graphical Abstract Repeated peripheral histamine or LPS exposure is associated with long-lasting, region-specific glial remodelling and attenuated 6-OHDA-induced dopaminergic injury.
- 4 November 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
Open AccessHistamine-Induced Peripheral Priming Promotes Region-Specific Glial Remodelling and Protects Against Dopaminergic Injury in a Mouse Model of Parkinson’s Disease
Peripheral immune priming can induce long-lasting changes in brain innate immune responses. In neurological diseases, including Alzheimer’s disease and stroke, inflammatory priming has been associated with neuroprotection, likely through microglial reprogramming. Here, we evaluated whether repeated peripheral histamine exposure was associated with persistent glial morphometric remodelling and with an altered response to subsequent dopaminergic injury. Adult male mice received four consecutive daily intraperitoneal injections of histamine, lipopolysaccharide (LPS), used as a reference peripheral immune-stimulating condition, or PBS. Three weeks later, glial morphometry was assessed in the substantia nigra (SN) and striatum (ST). In a separate cohort, mice underwent intrastriatal 6-hydroxydopamine (6-OHDA) lesion three weeks after priming. Motor behaviour, nigrostriatal TH immunoreactivity, apomorphine-evoked striatal neuronal recruitment and glial morphometric response were evaluated two weeks later. Under non-lesioned conditions, histamine and LPS exposure were associated with persistent microglial morphometric remodelling in the SN, whereas comparable ST changes were detected only after LPS. Astrocytic GFAP-based measures showed modest, non-significant trends in the SN. Following 6-OHDA lesion, prior histamine or LPS exposure reduced apomorphine-induced rotational asymmetry and was associated with greater preservation of tyrosine hydroxylase (TH) immunoreactivity in the nigrostriatal system. Histamine priming additionally increased apomorphine-evoked recruitment of DARPP-32-positive striatal neurons and attenuated lesion-associated microglial changes in the SN and ST. Astrocytic responses after lesion were region-dependent. Repeated peripheral histamine exposure was associated with persistent, region-specific glial morphometric remodelling and attenuated behavioural and dopaminergic deficits following subsequent 6-OHDA injury. These findings are compatible with long-lasting histamine-associated neuroimmune conditioning, although the underlying cellular and molecular mechanisms and the causal contribution of glial remodelling remain to be established. Graphical Abstract Repeated peripheral histamine or LPS exposure is associated with long-lasting, region-specific glial remodelling and attenuated 6-OHDA-induced dopaminergic injury.
- Open Access
- 18 December 2023
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 9 (1) , 1-16
Impaired neuron differentiation in GBA-associated Parkinson’s disease is linked to cell cycle defects in organoids
The mechanisms underlying Parkinson’s disease (PD) etiology are only partially understood despite intensive research conducted in the field. Recent evidence suggests that early neurodevelopmental defects might play a role in cellular susceptibility to neurodegeneration. To study the early developmental contribution of GBA mutations in PD we used patient-derived iPSCs carrying a heterozygous N370S mutation in the GBA gene. Patient-specific midbrain organoids displayed GBA-PD relevant phenotypes such as reduction of GCase activity, autophagy impairment, and mitochondrial dysfunction. Genome-scale metabolic (GEM) modeling predicted changes in lipid metabolism which were validated with lipidomics analysis, showing significant differences in the lipidome of GBA-PD. In addition, patient-specific midbrain organoids exhibited a decrease in the number and complexity of dopaminergic neurons. This was accompanied by an increase in the neural progenitor population showing signs of oxidative stress-induced damage and premature cellular senescence. These results provide insights into how GBA mutations may lead to neurodevelopmental defects thereby predisposing to PD pathology.
- 18 December 2023
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 9 (1) , 1-16
Open AccessImpaired neuron differentiation in GBA-associated Parkinson’s disease is linked to cell cycle defects in organoids
The mechanisms underlying Parkinson’s disease (PD) etiology are only partially understood despite intensive research conducted in the field. Recent evidence suggests that early neurodevelopmental defects might play a role in cellular susceptibility to neurodegeneration. To study the early developmental contribution of GBA mutations in PD we used patient-derived iPSCs carrying a heterozygous N370S mutation in the GBA gene. Patient-specific midbrain organoids displayed GBA-PD relevant phenotypes such as reduction of GCase activity, autophagy impairment, and mitochondrial dysfunction. Genome-scale metabolic (GEM) modeling predicted changes in lipid metabolism which were validated with lipidomics analysis, showing significant differences in the lipidome of GBA-PD. In addition, patient-specific midbrain organoids exhibited a decrease in the number and complexity of dopaminergic neurons. This was accompanied by an increase in the neural progenitor population showing signs of oxidative stress-induced damage and premature cellular senescence. These results provide insights into how GBA mutations may lead to neurodevelopmental defects thereby predisposing to PD pathology.
- Open Access
- 7 March 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (3) , 812
Synthesis, In Vitro Biological Evaluation of Antiproliferative and Neuroprotective Effects and In Silico Studies of Novel 16E-Arylidene-5α,6α-epoxyepiandrosterone Derivatives
Steroids constitute an important class of pharmacologically active molecules, playing key roles in human physiology. Within this group, 16E-arylideneandrostane derivatives have been reported as potent anti-cancer agents for the treatment of leukemia, breast and prostate cancers, and brain tumors. Additionally, 5α,6α-epoxycholesterol is an oxysterol with several biological activities, including regulation of cell proliferation and cholesterol homeostasis. Interestingly, pregnenolone derivatives combining these two modifications were described as potential neuroprotective agents. In this research, novel 16E-arylidene-5α,6α-epoxyepiandrosterone derivatives were synthesized from dehydroepiandrosterone by aldol condensation with different aldehydes followed by a diastereoselective 5α,6α-epoxidation. Their cytotoxicity was evaluated on tumoral and non-tumoral cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Furthermore, the assessment of the neuroprotective activity of these derivatives was performed in a dopaminergic neuronal cell line (N27), at basal conditions, and in the presence of the neurotoxin 6-hydroxydopamine (6-OHDA). Interestingly, some of these steroids had selective cytotoxic effects in tumoral cell lines, with an IC50 of 3.47 µM for the 2,3-dichlorophenyl derivative in the breast cancer cell line (MCF-7). The effects of this functionalized epoxide on cell proliferation (Ki67 staining), cell necrosis (propidium iodide staining), as well as the analysis of the nuclear area and near neighbor distance in MCF-7 cells, were analyzed. From this set of biological studies, strong evidence of the activation of apoptosis was found. In contrast, no significant neuroprotection against 6-OHDA-induced neurotoxicity was observed for the less cytotoxic steroids in N27 cells. Lastly, molecular docking simulations were achieved to verify the potential affinity of these compounds against important targets of steroidal drugs (androgen receptor, estrogen receptor α, and 5α-reductase type 2, 17α-hydroxylase-17,20-lyase and aromatase enzymes). This in silico study predicted a strong affinity between most novel steroidal derivatives and 5α-reductase and 17α-hydroxylase-17,20-lyase enzymes.
- 7 March 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (3) , 812
Open AccessSynthesis, In Vitro Biological Evaluation of Antiproliferative and Neuroprotective Effects and In Silico Studies of Novel 16E-Arylidene-5α,6α-epoxyepiandrosterone Derivatives
Steroids constitute an important class of pharmacologically active molecules, playing key roles in human physiology. Within this group, 16E-arylideneandrostane derivatives have been reported as potent anti-cancer agents for the treatment of leukemia, breast and prostate cancers, and brain tumors. Additionally, 5α,6α-epoxycholesterol is an oxysterol with several biological activities, including regulation of cell proliferation and cholesterol homeostasis. Interestingly, pregnenolone derivatives combining these two modifications were described as potential neuroprotective agents. In this research, novel 16E-arylidene-5α,6α-epoxyepiandrosterone derivatives were synthesized from dehydroepiandrosterone by aldol condensation with different aldehydes followed by a diastereoselective 5α,6α-epoxidation. Their cytotoxicity was evaluated on tumoral and non-tumoral cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Furthermore, the assessment of the neuroprotective activity of these derivatives was performed in a dopaminergic neuronal cell line (N27), at basal conditions, and in the presence of the neurotoxin 6-hydroxydopamine (6-OHDA). Interestingly, some of these steroids had selective cytotoxic effects in tumoral cell lines, with an IC50 of 3.47 µM for the 2,3-dichlorophenyl derivative in the breast cancer cell line (MCF-7). The effects of this functionalized epoxide on cell proliferation (Ki67 staining), cell necrosis (propidium iodide staining), as well as the analysis of the nuclear area and near neighbor distance in MCF-7 cells, were analyzed. From this set of biological studies, strong evidence of the activation of apoptosis was found. In contrast, no significant neuroprotection against 6-OHDA-induced neurotoxicity was observed for the less cytotoxic steroids in N27 cells. Lastly, molecular docking simulations were achieved to verify the potential affinity of these compounds against important targets of steroidal drugs (androgen receptor, estrogen receptor α, and 5α-reductase type 2, 17α-hydroxylase-17,20-lyase and aromatase enzymes). This in silico study predicted a strong affinity between most novel steroidal derivatives and 5α-reductase and 17α-hydroxylase-17,20-lyase enzymes.
- 1 February 2020
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 50, 38-45
New insights into the regulatory roles of microRNAs in adult neurogenesis
- 1 February 2020
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 50, 38-45
New insights into the regulatory roles of microRNAs in adult neurogenesis
- Open Access
- 10 June 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 8384
Histamine modulates hippocampal inflammation and neurogenesis in adult mice
Evidence points to a dual role of histamine in microglia-mediated neuroinflammation, a key pathological feature of several neurodegenerative pathologies. Moreover, histamine has been suggested as a modulator of adult neurogenesis. Herein, we evaluated the effect of histamine in hippocampal neuroinflammation and neurogenesis under physiological and inflammatory contexts. For that purpose, mice were intraperitoneally challenged with lipopolysaccharide (LPS) followed by an intrahippocampal injection of histamine. We showed that histamine per se triggered glial reactivity and induced mild long-term impairments in neurogenesis, reducing immature neurons dendritic volume and complexity. Nevertheless, in mice exposed to LPS (2 mg/Kg), histamine was able to counteract LPS-induced glial activation and release of pro-inflammatory molecules as well as neurogenesis impairment. Moreover, histamine prevented LPS-induced loss of immature neurons complexity as well as LPS-induced loss of both CREB and PSD-95 proteins (essential for proper neuronal activity). Altogether, our results highlight histamine as a potential therapeutic agent to treat neurological conditions associated with hippocampal neuroinflammation and neurodegeneration.
- 10 June 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 8384
Open AccessHistamine modulates hippocampal inflammation and neurogenesis in adult mice
Evidence points to a dual role of histamine in microglia-mediated neuroinflammation, a key pathological feature of several neurodegenerative pathologies. Moreover, histamine has been suggested as a modulator of adult neurogenesis. Herein, we evaluated the effect of histamine in hippocampal neuroinflammation and neurogenesis under physiological and inflammatory contexts. For that purpose, mice were intraperitoneally challenged with lipopolysaccharide (LPS) followed by an intrahippocampal injection of histamine. We showed that histamine per se triggered glial reactivity and induced mild long-term impairments in neurogenesis, reducing immature neurons dendritic volume and complexity. Nevertheless, in mice exposed to LPS (2 mg/Kg), histamine was able to counteract LPS-induced glial activation and release of pro-inflammatory molecules as well as neurogenesis impairment. Moreover, histamine prevented LPS-induced loss of immature neurons complexity as well as LPS-induced loss of both CREB and PSD-95 proteins (essential for proper neuronal activity). Altogether, our results highlight histamine as a potential therapeutic agent to treat neurological conditions associated with hippocampal neuroinflammation and neurodegeneration.